87 results about "Oncology field" patented technology

The invention belongs to the fields of gene engineering and oncology and discloses a serum / plasma miRNA marker associated with breast cancer and application thereof. The marker is a combination of miR-16, miR-25, miR-222 and miR-324-3p. The maker and primers thereof can be used for preparing a diagnosis kit and assisting early diagnosis of the breast cancer.

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and / or preventing various diseases and disorders by administering the humanized anti-αvβ6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin αvβ6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment / prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αvβ6.

The invention relates to a kit for auxiliary diagnosis of multiple tumors by taking a micro ribonucleic acid (RNA) combination as a tumor marker, and a detection method of the kit. The invention belongs to the fields of genetic engineering and oncology. The detection method comprises the steps of (1) extracting RNA from serum; (2) carrying out polyadenylation on the 3' end of micro RNA; (3) purifying and recovering a tailing product; (4) carrying out an inverse transcription reaction on the tailing product; (5) testing the relative expression of the micro RNA by means of a fluorescent quantitative PCR (polymerase chain reaction); (6) analyzing the result of the fluorescent quantitative PCR. The kit has the characteristics of high conservative property, space-time specificity, stability, tissue specificity and the like, and plays an important role in the aspects such as disease pathogenesis research, early diagnosis, individualized treatment and prognosis; furthermore, the kit is simple to operate, convenient in material obtaining, safe and noninvasive, and is conveniently used for screening of a great deal of diseases.

The invention belongs to the fields of gene engineering and oncology, and discloses a serum / plasma miRNA serum marker related to cervical carcinoma and precancerous lesions thereof and application thereof. The marker is single miR-21 or the combination of miR-21 and miR-29a. The marker and the primer thereof can be used for preparing diagnosis kits which are used for assistant early diagnosis of cervical carcinoma and precancerous lesions thereof.

The invention relates to the field of radiation oncology, specifically the use of novel radio-opaque fiduciary markers which resist migration within tissues, which may be implanted in the body and imaged during radio-therapy to insure accurate treatment of target regions while avoiding irradiation of non-target regions. In one embodiment, the markers comprise oblong bodies from which a plurality of short tines protrude. Also provided are novel devices for implanting such markers. Additionally, the invention provides methods of delineating tumor resection beds and whole-bladder contours in the radiotherapeutic treatment of bladder cancer. Lastly, the invention encompasses novel methods of delivering fiduciary markers and other implants and materials by needle with sealing aids that increase the retention rate of the delivered markers, implants, or materials.

The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment / prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and / or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.

The invention belongs to the fields of genetic engineering and oncology, and discloses a blood serum / blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof. The marker is formed by combining miR-451 and miR-490-3p. The marker and primers of the marker can be used for preparing a diagnostic kit and are used for the auxiliary diagnosis of pancreatic cancer.

The present invention relates to water-soluble taxanes covalently bounded tohyaluronic acid or hyaluronic acid derivatives, and in particular to paclitaxel and docetaxel, useful for the preparation of pharmaceutical compositions to be used in the field of oncology, in the treatment of autoimmune disorders and of restenosis. The invention also relates to the process for preparing taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives by direct synthesis between molecules of hyaluronic acid and of taxane or by indirect synthesis by the introduction of a spacer between the hyaluronic acid or hyaluronic acid derivative and the taxane.

The invention belongs to the field of genetic engineering and phymatology, in particular to a blood serum / blood plasma miRNA marker related to non-small cell lung cancer (SCLC) prognosis and an application thereof. The marker is one or more of miR-486, miR30d, miR-1 or miR-499 and can be used for preparing an auxiliary diagnostic reagent kit for the non-SCLC prognosis or a medicine for treating the SCLC.

The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

The invention relates to the fields of molecular biology and phymatology, and discloses an application of a biomarker associated with a colorectal cancer. The marker is PIK3C2G, and particularly, deoxyribonucleic acid (DNA) of the marker is inversely related to survival time after colorectal cancer occurrence and chemotherapy of a sufferer relative to copy number variation. The invention also relates to a primer pair, a kit and a method for detecting the PIK3C2G in a colorectal cancer, the primer pair for detecting the PIK3C2G and a primer pair for detecting a reference gene reduced glyceraldehyde-phosphate dehydrogenase(GAPDH) are contained in the kit of the PIK3C2G. An upstream primer base sequence is shown in SEQ ID NO:1. The primer can be applied to detection of the copy number variation of the PIK3C2G through polymerase chain reaction (PCR) amplification, so that detection of the colorectal cancer and evaluation of the curative effect of oxaliplatin (FOLFOX) chemotherapy of the colorectal cancer through the PIK3C2G become possible.

The present invention relates to the field of oncology and provides novel compositions and methods for diagnosing and treating pancreatic cancer. In particular, the present invention provides pancreatic cancer stem cells useful for the study, diagnosis, and treatment of solid tumors.

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and / or preventing various diseases and disorders by administering the humanized anti-αvβ6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin αvβ6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment / prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αvβ6.

The invention belongs to the fields of genetic engineering and oncology, and discloses an SNP marker related to liver toxicity of platinum type chemotherapeutic medicines and applications thereof. The marker is a composition of rs6681909, rs4140932, rs13131227, rs4446279, rs17053350, rs9402873, rs16878272, rs13267737, rs7008590, rs947853, rs2838566, rs1383888, rs9642723, rs3822296, rs2160046, rs10002931, rs10032941, rs6449138, rs1048037 and rs10086636. The marker and primer probes thereof can be used for preparing a diagnosis kit of the liver toxicity of platinum type chemotherapeutic medicines, and are good in sensitivity and specificity.

The invention relates to the field of immunology, endocrinology and oncology and, in particular, the generation of a combined immune response to determined growth factors and hormones. A synergic effect, outlined herein, between growth regulating factors (EGF, TGF and VEGF) and hormones involved in the sexual hormones release cascade or reproduction (GnRH, LH, FSH) stimulates the anti-tumor response which is expressed as a reduction in the tumor mass and an increase in the survival time.

The invention belongs to the fields of genetic engineering and oncology and discloses an internal reference for detecting miRNA (micro Ribonucleic Acid) in serum / blood plasma and application of the internal reference. The internal reference is separate miR-484 or miR-191 or a combination of the miR-191 and the miR-484. The internal reference and a primer of the internal reference can be used for preparing an internal reference detection kit which is used for detecting the internal reference of the miRNA in serum / blood plasma.

The invention discloses a circRNA marker associated with early diagnosis of colorectal cancer, a detection primer, a reagent kit and an application of the circRNA marker, and belongs to the fields ofgenetic engineering and oncology. The circRNA marker associated with early diagnosis of colorectal cancer is has-circ-007667, and circRNA shows specific low expression in colorectal cancer tissues, and does not show such specificity low expression in normal tissue, so that the has-circ-007667 can be used as a specific molecular marker to improve the diagnosis efficiency of the colorectal cancer, and can also be used for early assistance diagnosis of clinical colorectal cancer. The specific detection primer synthesized according to a has-circ-007667 sequence can be used for detecting the expression level of the has-circ-007667 in samples, so that the sensibility and the specificity for clinical colorectal cancer early diagnosis can be improved, and the detection results are accurate and stable.

The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin αvβ6, and the responsiveness of patient populations to αvβ6-active compounds and compositions (e.g., antibodies and other ligands that bind αvβ6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such αvβ6-active compounds and compositions by examining the expression of αvβ6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment / prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin αvβ6 on the surfaces of tumor cells and / or that block one or more components of the TGF-β pathway, particularly in smad4-deficient tumor cells.

The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.

The invention relates to the field of medical equipment and oncology, and relates to a puncture biopsy needle with optical fiber probes. The puncture biopsy needle with optical fiber probes mainly comprises a host machine, a puncture needle, optical fiber probes and a display device, wherein the optical fiber probes are arranged on the outer edge of a needle core of the puncture biopsy needle. According to the puncture biopsy needle, the optical fiber probes are adopted to transmit lasers to the tip of the puncture biopsy needle, and therefore the real-time acquisition of Raman spectrum signals of pinpoint contact tissues or cells is achieved, and the signals are automatically analyzed and monitored. When the puncture biopsy needle is used, the Raman spectrum of the pinpoint tissues and cells can be monitored in real time in punctures, and by acquiring information of cancerous status and the like of the current needle tip contact tissues and cells through analyzing spectrum signals, tumors can be identified from normal tissues in real time in punctures, which helps doctors to find out cancerous tissues through biopsy more precisely, therefore the positive rate of biopsy is increased, complications caused by vascular injury and other normal tissue injuries are avoided, and the safety of punctures is improved.

The invention provides a plasma miRNA biomarker related to colorectal cancer diagnosis and an application thereof, and belongs to the field of biotechnology and oncology. The plasma miRNA biomarker related to colorectal cancer diagnosis is plasma miR-21. The present study suggests that plasma miRNAs are mainly from secretion of tumor tissues or are induced by death and dissociation of tumor cells, but the miRNAs with differential expression in the tissues do not absolutely experience differential expression in the plasma, and some miRNAs are even reverse. Although the miR-21 has been determined to be capable of being used as the marker in colorectal cancer tissues, results in the reports of peripheral plasma samples are not uniform, the innovation of the invention lies in that the expression trend uniformity of the plasma miR-21 and the tissue miR-21 is determined, the plasma miR-21 can be used as a diagnostic marker and is non-invasive, so that the plasma miR-21 can be applied to future clinic.

The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.

The invention belongs to the field of molecular biology and oncology, and particularly relates to a group of esophageal cancer detection markers and application thereof in preparation of an esophagealcancer screening kit. The esophageal cancer detection markers serve a reagent capable of specifically detecting CA19-9, CYFRA21-1, CA125, FBXW7 and FAT1 or a group of gene expression products; the esophageal cancer early diagnosis kit is a liquid-phase protein chip kit. According to the esophageal cancer marker, a combination of the CA19-9 monoclonal antibody, the CYFRA21-1 monoclonal antibody, the CA125 monoclonal antibody, the FBXW7 monoclonal antibody and the FAT1 monoclonal antibody is used as the esophageal cancer marker for the first time, and is applied to preparation of a liquid-phaseprotein chip with high detection sensitivity and specificity for early esophageal cancer, the detection sensitivity of the liquid-phase protein chip to esophageal cancer is 93.5%, and the specificityof the liquid-phase protein chip to esophageal cancer is 73.9%.

The invention belongs to the field of medical immunology and oncology and discloses thymus-dependent lymphocyte antigen epitope peptides of primary liver cancer related antigens and application thereof. The antigen epitope peptides are antigen peptides separately restricted by HLA-A0201, HLA-A1101, hLA-A2402, HLA-A3101, HLA-A0206, HLA-A0207, HLA-A3303, HLA-A3001, HLA-A0203, HLA-A1102, HLA-A0301, HLA-A0101 and HLA-A2601 molecules, and the varieties of the antigen epitope peptides sum to 110. The antigen epitope peptides can specifically bind to cytotoxic thymus-dependent lymphocytes so as to stimulate the activation, proliferation and differentiation of the thymus-dependent lymphocytes, so anti-tumor immune effect is exerted; the antigen peptides can be used for preparing therapeutic and preventive vaccines for liver cancer, can also be used for preparing detection reagents for detecting liver cancer-related antigen-specific cytotoxic thymus-dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of liver cancer.

The invention belongs to the field of genetic engineering and oncology, and relates to a breast cancer marker SGOL1. The inventor researches different comparative cell systems, results show that an SGOL1 coded sequence is completely lowly expressed in normal cells and tissue of mammary gland and is remarkably highly expressed in tumor cells, and in addition expression of the gene is remarkably related to clinical pathology parameters. The SGOL1 provided by the invention can be used as a specific tumor marker for early-stage detection on breast cancer or a treatment target, and has significant clinical application values.

The invention belongs to the fields of genetic engineering and oncology, and discloses a serum / plasma miRNA marker for early diagnosis of noncardiac gastric carcinoma and applications thereof. The marker is a composition of miR-16, miR-25, miR-92a, miR-451 and miR-486-5p. The marker and primers thereof can be used for preparing a diagnosis kit, and used for assistant early diagnosis of the noncardiac gastric carcinoma.